Video
Combination neoadjuvant nivolumab/gemcitabine-cisplatin is efficacious in pathologically downstaging MIBC
Author(s):
“The complete response rates were 49%, which is quite impressive compared to historical controls,” says Shilpa Gupta, MD.
Video Player is loading.
In this video, Shilpa Gupta, MD, discusses the background and findings of the study, “Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Gupta is the director of genitourinary oncology at Cleveland Clinic in Ohio.
Related Videos
How recombinant BCG could ease strain of supply issues
Katherine Chan, MD, on viral vs non-viral vectors in bladder cancer
John Taylor, III, MD, on novel options in NMIBC
Suzanne B. Merrill, MD, FACS, on EAP program for recombinant BCG
What a long-term study of patients undergoing RARC reveals about upstaging
Sima Porten, MD, on the increased risk of bladder cancer among firefighters
Jason Hafron, MD, predicts coming advancements in bladder cancer
Laura Bukavina, MD, on trial of radiation with concurrent sacituzumab govitecan in MIBC
Chad Reichard, MD, on the Expanded Access Program for recombinant BCG
Neeraja Tillu, MD, discusses predictors of upstaging following RARC for NMIBC
Related Content
